31
Participants
Start Date
April 19, 2022
Primary Completion Date
June 24, 2025
Study Completion Date
August 26, 2025
vobramitamab duocarmazine
Vobramitamab duocarmazine is an antibody drug conjugate (ADC) targeted against B7-H3.
lorigerlimab
Lorigerlimab is a bispecific DART® molecule that binds PD-1 and CTLA-4.
Weill Cornell Medicine, New York
University of Pittsburgh Medical Center, Hillman Cancer Center, Pittsburgh
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore
University of Virginia Comprehensive Cancer Center, Charlottesville
Carolina BioOncology, Huntersville
Winship Cancer Institute of Emory University, Atlanta
Florida Cancer Specialists and Research Institute, Sarasota
Stephenson Cancer Center, The University of Oklahoma, Oklahoma City
University of California, Los Angeles, Los Angeles
University of California, San Francisco, San Francisco
Lead Sponsor
MacroGenics
INDUSTRY